News Releases

Filter News Releases by year:
2024 | 2023 | 2022 | 2021 | 2020

13 Results

October 2022

Monoclonal Antibody Prevents Malaria Infection in African Adults

October 31, 2022

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can prevent malaria infection in an endemic region.

June 2022

Trial of Potential Universal Flu Vaccine Opens at NIH Clinical Center

June 28, 2022

A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The placebo-controlled trial will test the safety of a candidate vaccine, BPL-1357, and its ability to prompt immune responses. The vaccine candidate was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). The single-site trial can enroll up to 100 people aged 18 to 55 years and is led by NIAID investigator Matthew J. Memoli, M.D.

March 2022

NIH Launches Trial to Study Allergic Reactions to COVID-19 mRNA Vaccine

March 9, 2022

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) are conducting a clinical trial designed to help understand rare but potentially serious systemic allergic reactions to COVID-19 mRNA vaccines. The single-site trial will enroll up to 100 people aged 16 to 69 years old who had an allergic reaction to a first dose of COVID-19 mRNA vaccines. Study participants will receive a second dose of vaccine as inpatients under carefully controlled conditions at the NIH Clinical Center in Bethesda, Maryland.

December 2021

NIH Scientists Urge Pursuit of Universal Coronavirus Vaccine

December 16, 2021

A growing body of scientific evidence, considered together with ecological reality, strongly suggests that novel coronaviruses will continue to infect bats and other animal reservoirs and potentially emerge to pose a pandemic threat to humans.

Experimental mRNA HIV Vaccine Safe, Shows Promise in Animals

December 9, 2021

An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their results, published in Nature Medicine, show that the novel vaccine was safe and prompted desired antibody and cellular immune responses against an HIV-like virus.

September 2021

NIAID Scientists Find a Key to Hepatitis C Entry into Cells

September 21, 2021

Understanding Structure of HCV Proteins Could Aid in Vaccine Development

June 2021

Investigational Malaria Vaccine Gives Strong, Lasting Protection

June 30, 2021

Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country.

May 2021

Gene Therapy Restores Immune Function in Children with Rare Immunodeficiency

May 11, 2021

An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health.

April 2021

COVID-19 Vaccine Responses to be Studied in People with Immune Deficits

April 23, 2021

A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims to enroll 500 people, 400 with primary or secondary immune system disorders and 100 without such conditions. 

March 2021

T Cells Recognize Recent SARS-CoV-2 Variants

March 30, 2021

When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues analyzed blood cell samples from 30 people who had contracted and recovered from COVID-19 prior to the emergence of virus variants.

January 2021

Media Availability—NIH Officials Highlight COVID-19 Vaccine Facts, Unknowns for Healthcare Providers

January 18, 2021

NIAID Director urges healthcare providers to be able to explain the latest data supporting the safety and efficacy of vaccines for COVID-19.

September 2020

Probiotic Skin Therapy Improves Eczema in Children, NIH Study Suggests

September 9, 2020

An experimental treatment for eczema safely reduced disease severity and increased quality of life for children as young as 3 years old, NIH study shows.

July 2020

Kidney Transplantation Between People with HIV is Safe, NIH Study Finds

July 23, 2020

NIH Study finds that kidney transplantation between people with HIV is safe, making more kidneys available for those awaiting a transplant.